Stem cell therapy for heart failure: Distinct mechanisms and therapeutic implications in heart failure with reduced ejection fraction and heart failure with preserved ejection fraction
New Cell · 16.11.2025
DOI: 10.61958/ncjf2750 ↗Kurz gefasst
Fachartikel in der Zeitschrift New Cell, online erschienen am 16.11.2025. Verfasst von Ya-Xi Yue. Die Arbeit nennt 94 Literaturangaben.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Heart failure remains a leading cause of morbidity and mortality worldwide, posing an escalating public health challenge despite advances in pharmacological and device-based therapies. Classified by left ventricular ejection fraction (LVEF), heart failure includes heart failure with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF), which differ in pathophysiology and therapeutic response. HFrEF is primarily associated with ischemic injury and cardiomyocyte loss, resulting in systolic dysfunction and adverse ventricular remodeling, whereas HFpEF arises from systemic inflammation, endothelial dysfunction, and myocardial fibrosis, often linked to comorbidities such as obesity, hypertension, and diabetes. Conventional treatments mainly alleviate symptoms but fail to repair myocardial damage or reverse fibrotic remodeling, highlighting the need for regenerative strategies. Stem cell therapy has emerged as a promising approach capable of targeting the distinct pathological mechanisms of HFrEF and HFpEF. In HFrEF, mesenchymal stem cells (MSCs), cardiac progenitor cells (CPCs), endothelial progenitor cells (EPCs), and induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) can restore cardiac function by promoting angiogenesis, inhibiting apoptosis, and modulating fibrosis. In contrast, stem cell therapy for HFpEF focuses on mitigating inflammation, improving endothelial function, and reducing diastolic stiffness. Clinical studies in HFrEF have demonstrated encouraging safety and functional improvements, particularly with MSCs and CPCs, while research in HFpEF remains largely preclinical. Recent advances in hiPSC-derived cardiac organoid models that mimic HFpEF pathophysiology may accelerate translational studies. Collectively, stem cell therapy represents a paradigm shift toward myocardial regeneration and disease modification, offering distinct therapeutic potential for both HFrEF and HFpEF.
Zitieren
APA
Yue, Y. (2025). Stem cell therapy for heart failure: Distinct mechanisms and therapeutic implications in heart failure with reduced ejection fraction and heart failure with preserved ejection fraction. New Cell. https://doi.org/10.61958/ncjf2750
Vancouver
Yue Y. Stem cell therapy for heart failure: Distinct mechanisms and therapeutic implications in heart failure with reduced ejection fraction and heart failure with preserved ejection fraction. New Cell. 2025. doi:10.61958/ncjf2750
BibTeX
@article{Yue2025,
author = {Yue, Ya-Xi},
title = {Stem cell therapy for heart failure: Distinct mechanisms and therapeutic implications in heart failure with reduced ejection fraction and heart failure with preserved ejection fraction},
journal = {New Cell},
year = {2025},
doi = {10.61958/ncjf2750}
}
EUVIMED